TGFB2 and melanoma: Gabriely et al. [430] developed two new anti-LAP mouse mAbs (against TGF-β1 LAP) and tested their effect on antitumor immune responses in syngeneic mouse models of melanoma, colorectal carcinoma, and GBM.